Drugs and patents in ATC class V06DC

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
FLUDEOXYGLUCOSE F18	fludeoxyglucose f-18
>Tradename	>Generic Name

Last updated: July 3, 2026

ATC V06DC comprises carbohydrate-containing drugs used to correct metabolic or nutritional deficits and to support specific therapeutic dosing regimens. The competitive structure is fragmented across multiple carbohydrate actives and dosage forms (oral liquids, powders, enteral feeds), with patent estates that tend to be activity- and formulation-specific rather than dominated by single platform patents across the class. From a commercial risk perspective, launch timelines are usually governed by (1) composition-of-matter and formulation patents around specific carbohydrate entities and specific preparations (including stabilizers, gelling agents, and solubilization systems), (2) method-of-use patents tied to patient subgroups and clinical protocols, and (3) exclusivity rules tied to FDA/EMA reference products when applicable.

This report maps the market dynamics typical for V06DC and outlines the patent landscape structure investors and litigators should assume for the class, with a focus on the kinds of Orange Book (US) listings, paragraph IV risk patterns, and litigation triggers that repeatedly affect carbohydrate therapies.

Which drugs fall under ATC V06DC (Carbohydrates), and what market dynamics shape them?

ATC V06DC is a therapeutic ATC bucket rather than a single active ingredient, so market dynamics are driven by the underlying carbohydrate(s), manufacturing constraints, and how each product is reimbursed and administered.

Common commercial drivers across V06DC

Dose intensity and administration workflow: Many carbohydrate products are administered orally or via enteral routes, so pharmacy handling, shelf stability, and mixing performance drive formulary adoption.
Clinical protocol lock-in: Products often become preferred when they integrate into standardized feeding or repletion protocols (method-of-use patents and protocol-based reimbursement support this).
Bioavailability and osmolality constraints: For carbohydrate solutions and powders, osmolality, viscosity, and stability limit substitution. These technical parameters often map to formulation IP.
Manufacturing quality systems: Scale-up from powder to ready-to-use liquid or reconstitutable solutions stresses control of moisture, particle size distribution, and impurity profiles. Competitors can face IP barriers tied to manufacturing methods and impurity specs.
Substitution and wholesaler dynamics: Some V06DC products behave like “specialty generics,” where multiple suppliers exist with limited clinical differentiation, but switching is slowed by payer coverage rules and product availability.

What patents protect carbohydrate drugs in ATC V06DC, and what is the typical patent “estate structure”?

For V06DC, the patent estate typically clusters into four layers.

1) Composition-of-matter around the specific carbohydrate entity

Patents may cover a particular carbohydrate structure, derivative, or defined molecular characteristics.
For naturally sourced carbohydrates, patents more often cover purification, defined specifications, and defined impurity profiles rather than “new” molecules.

2) Formulation patents tied to stability and administration

Ready-to-use solutions and reconstitutable powders frequently have IP around:
- buffers and pH targets
- stabilizers, emulsifiers, and viscosity modifiers
- solubilization or dispersion methods
- osmolality control to reduce GI intolerance
- compatibility with enteral feeding equipment

3) Method-of-use patents tied to clinical protocols

Method-of-use is common where differentiation depends on patient selection or dosing schedules:
- dosing regimens (timed repletion)
- specific indications (metabolic support, replacement therapy settings)
- administration route (oral vs enteral) with defined preparation steps

4) Manufacturing process patents and control of impurities

Process patents cover:
- purification steps
- crystallization or drying methods
- impurity removal and specification windows

What this means for freedom-to-operate (FTO)

V06DC products rarely clear quickly based on a single “composition-of-matter” expiration. An FTO review should treat formulation and method-of-use as first-order constraints, especially when the competitor’s product is marketed to the same administration setting.

Which patent expirations most influence generics for ATC V06DC, and when do key exclusivity windows end?

Carbohydrate class expirations usually split into two timelines.

A) Hard patent expiry (US/EP)

Composition-of-matter patents can expire first, but formulation and method-of-use patents often extend practical exclusivity through:
- patent family continuations
- formulation-specific claims that remain infringed by the generic’s marketed product
- process patents that restrict manufacturing at scale

B) Regulatory exclusivity (when applicable)

If a given carbohydrate drug is approved under a regulatory exclusivity regime (for example, New Chemical Entity or certain supplemental exclusivities), the practical “no generic competition” period can be longer than hard patent expiry.

Generic launch timing risk pattern

If the reference product has intact formulation/method-of-use patents, a competitor’s paragraph IV strategy may still fail on:
- infringement (product-by-process or direct infringement on dosage form claims)
- invalidity (obviousness based on known carbohydrates and common excipients is often contested)
- estoppel and settlement terms

How does the Orange Book status of carbohydrate drugs affect paragraph IV generic entry risk?

Orange Book-driven entry risk depends on whether the carbohydrate brand lists:

drug product patents (formulation and manufacturing-related)
method-of-use patents
multiple blocking patents across dosage forms

Typical V06DC Orange Book patterns

More than one listed patent per brand: Formulation and method-of-use usually appear alongside product patents.
Late-listed patents: Continuations or supplemental patents can appear over time, shifting the paragraph IV assessment.
Multiple dosage strengths/forms: If the brand has multiple SKU strengths or reconstitution formats, a competitor must clear patents applicable to its exact marketed strength and form.

Paragraph IV practical implication

In V06DC, the generic product often must be more than “the same active.” It must also align with:

stability and preparation steps that avoid infringement of formulation claims
dosing and indication labeling that avoids method-of-use claims

What formulations are most commonly patented in carbohydrate (V06DC) products?

Formulation patents in this class concentrate on variables that affect:

handling
patient tolerance
stability during storage and after reconstitution
compatibility with enteral delivery systems

Formulation claim targets frequently seen

Defined concentration ranges for the carbohydrate in liquid or reconstitutable form
pH and buffer systems used to prevent degradation
viscosity and rheology modifiers affecting flow in feeding tubes
stabilizers to limit browning, precipitation, or microbial risk
osmolality targets linked to tolerability
reconstitution instructions and order-of-addition steps that can be claimed as part of preparation
packaging-associated constraints (sometimes indirectly via stability and leachables controls)

Which method-of-use patents create labeling and switching barriers for carbohydrate therapies?

Method-of-use patents can constrain:

what dosing regimen appears on the label
which patient subgroup is targeted
administration route instructions

Typical method-of-use structures

“A method for treating” a defined clinical condition by administering a carbohydrate formulation with:
- a specific dosing interval
- a specific daily dose range
- a specific route and preparation sequence
- a defined patient characteristic (for example, disease state, age range, or treatment setting)

Generic switching effect

Even if a generic matches composition and strength, it may face:

a “skinny label” requirement
payer resistance if the label is not aligned with the preferred protocol
litigation if labeling still infringes a method-of-use claim

How strong is the patent estate for ATC V06DC carbohydrates, and where do weak spots typically exist?

Strength factors that usually favor incumbents

Formulation patents can be harder to design around when:
- the claim is broad across concentration ranges
- stability or osmolality constraints are central to product performance
Method-of-use patents are powerful when:
- dosing regimens are tightly tied to clinical protocol standards
Manufacturing patents can be difficult to circumvent because:
- impurity controls are tied to regulatory filings

Common weak spots

Narrow claim scope tied to specific excipient combinations: if the competitor’s formulation uses different stabilizers or viscosity modifiers, infringement risk can drop.
Overbreadth attacks on formulation concentration ranges: invalidity arguments may succeed if prior art teaches the same range and the claimed effect is not supported by data.
Indefiniteness in manufacturing claims: if process steps are described by functional parameters without clear boundaries, invalidity can be argued.

What generic entry risks exist for carbohydrate brands in V06DC if competitors file paragraph IV certifications?

Most frequent litigation entry points

Paragraph IV certifications against formulation and method-of-use patents.
Product-by-product challenge where competitor argues it is “non-infringing” due to:
- different excipient selection
- different preparation steps
- different dosing schedule or labeling

Settlement dynamics

Carbohydrate brand settlements often include:

non-launch commitments for specified strengths and dosage forms
“at-risk” launch triggers tied to design changes
cross-licensing around manufacturing processes

Operational consequence

Competitors should model three scenarios:

at-risk launch despite ongoing litigation
delayed launch via settlement
label carve-out limiting clinical protocol compatibility

What patent litigation affects the carbohydrate (V06DC) competitive landscape?

Litigation in this class is usually concentrated around:

infringed formulation patents (product composition and preparation)
infringed method-of-use patents (labeling and dosing protocol)
validity disputes around obviousness for known carbohydrates and excipients

Who tends to litigate

Incumbent branded manufacturers of niche carbohydrate therapies
Multiple generic entrants challenging the same listed patents across the same dosage forms

Typical case outcomes that matter commercially

Win or loss on formulation claims frequently determines whether a competitor can market its product without a settlement.
Wins on validity can open the door to multiple generics quickly, compressing pricing.

How does the carbohydrate supply chain influence patent and commercial strategy in V06DC?

Manufacturing constraints drive both IP and pricing

Patents tied to manufacturing steps or impurity profiles can:
- limit short-term competition
- raise cost of alternative manufacturing lines
Quality controls become commercial differentiators when:
- purity and stability translate into fewer adverse events or fewer handling failures
- tender processes specify quality metrics that mirror claimed specs

Inventory and procurement

Carbohydrate therapies can be sensitive to:
- raw material availability
- drying and packaging shelf-life
- distribution constraints
  These factors affect launch timing and can determine whether a competitor enters promptly after exclusivity ends.

How does ATC V06DC compare with other ATC carbohydrate-adjacent categories in patent risk and exclusivity?

Compared with adjacent therapeutic categories that rely heavily on a single molecule:

V06DC’s risk is more “portfolio-based” per brand because differentiation often sits in formulation and protocol rather than in the base carbohydrate alone.
Patent estates are therefore more likely to require full claim-map coverage across:
- active + excipients
- product form
- label instructions
- manufacturing steps

Key takeaways on market dynamics and the patent landscape for V06DC carbohydrates

V06DC is a category-level umbrella; competitive outcomes depend on specific carbohydrate actives, dose forms, and protocol integration.
Patent estates typically split across composition-of-matter, formulation, method-of-use, and manufacturing process layers.
Orange Book status, especially multiple listed drug product and method-of-use patents, drives paragraph IV risk more than a single composition patent.
Generics face entry barriers when formulation performance and labeling protocol claims remain intact.
Litigation in this class usually turns on formulation and method-of-use infringement and on validity arguments tied to excipient and concentration ranges.

FAQs

1) Which patents typically block generic entry for carbohydrate products in ATC V06DC?

Drug product (formulation/manufacturing) patents plus method-of-use patents covering dosing regimens and label instructions.

2) What design-arounds most often reduce infringement risk for V06DC carbohydrate generics?

Changing excipient selection and formulation-specific concentration ranges, and aligning labeling to avoid claimed dosing protocols.

3) Do V06DC carbohydrate brands usually have multiple Orange Book listed patents per dosage form?

Yes. Fragmented estates across formulation and method-of-use are common, creating layered blocking risk.

4) How do manufacturing-process patents affect V06DC generic launch timelines?

They can restrict commercial viability even when formulation and labeling can be designed around, because process claims can be harder to circumvent without changing upstream manufacturing steps.

5) What settlement terms are most common in carbohydrate (V06DC) patent disputes?

Non-launch or delayed-launch commitments by strength/form, sometimes tied to design changes and label carve-outs.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-07-03).
European Medicines Agency. Public assessment reports and medicine details. European Medicines Agency. (Accessed 2026-07-03).
WHO. ATC Classification. World Health Organization Collaborating Centre for Drug Statistics Methodology. (Accessed 2026-07-03).